Heart Failure Treatment in 2023: Is There a Place for Lipid
Lowering Therapy?

J 2023

Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?

POLOCZKOVÁ, Hana and Jan KREJČÍ

Basic information

Original name

Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?

Authors

POLOCZKOVÁ, Hana (203 Czech Republic, belonging to the institution) and Jan KREJČÍ (203 Czech Republic, belonging to the institution)

Edition

CURRENT ATHEROSCLEROSIS REPORTS, PHILADELPHIA, CURRENT MEDICINE GROUP, 2023, 1523-3804

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.800 in 2022

RIV identification code

RIV/00216224:14110/23:00133673

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s11883-023-01166-3

UT WoS

001118155800003

Keywords in English

Heart failure; Dyslipidemia; Lipid lowering therapy; Statins; PCSK9 inhibitors

Abstract

V originále

Purpose of ReviewAn evidence for lipid lowering therapy in heart failure is briefly summarized in this review.Recent FindingsHeart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated.SummaryBased on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use.

Links

LX22NPO5104, research and development project

Name: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění (Acronym: CarDia)

Investor: Ministry of Education, Youth and Sports of the CR, 5.1 EXCELES

Citovat

POLOCZKOVÁ, Hana and Jan KREJČÍ. Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy? CURRENT ATHEROSCLEROSIS REPORTS. PHILADELPHIA: CURRENT MEDICINE GROUP, 2023, vol. 25, No 12, p. 957-964. ISSN 1523-3804. Available from: https://dx.doi.org/10.1007/s11883-023-01166-3.

@article{2379567,
   author = {Poloczková, Hana and Krejčí, Jan},
   article_location = {PHILADELPHIA},
   article_number = {12},
   doi = {http://dx.doi.org/10.1007/s11883-023-01166-3},
   keywords = {Heart failure; Dyslipidemia; Lipid lowering therapy; Statins; PCSK9 inhibitors},
   language = {eng},
   issn = {1523-3804},
   journal = {CURRENT ATHEROSCLEROSIS REPORTS},
   title = {Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?},
   url = {https://link.springer.com/article/10.1007/s11883-023-01166-3},
   volume = {25},
   year = {2023}
}

TY  - JOUR
ID  - 2379567
AU  - Poloczková, Hana - Krejčí, Jan
PY  - 2023
TI  - Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?
JF  - CURRENT ATHEROSCLEROSIS REPORTS
VL  - 25
IS  - 12
SP  - 957-964
EP  - 957-964
PB  - CURRENT MEDICINE GROUP
SN  - 15233804
KW  - Heart failure
KW  - Dyslipidemia
KW  - Lipid lowering therapy
KW  - Statins
KW  - PCSK9 inhibitors
UR  - https://link.springer.com/article/10.1007/s11883-023-01166-3
N2  - Purpose of ReviewAn evidence for lipid lowering therapy in heart failure is briefly summarized in this review.Recent FindingsHeart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated.SummaryBased on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use.
ER  -

POLOCZKOVÁ, Hana and Jan KREJČÍ. Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy? \textit{CURRENT ATHEROSCLEROSIS REPORTS}. PHILADELPHIA: CURRENT MEDICINE GROUP, 2023, vol.~25, No~12, p.~957-964. ISSN~1523-3804. Available from: https://dx.doi.org/10.1007/s11883-023-01166-3.

Detailed Information on Publication Record